(PharmaNewsWire.Com, January 10, 2017 ) The report “European Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90)), by Application (Oncology, Thyroid, Cardiology) - Forecasts to 2020”, analyzes and studies the major market drivers, restraints, challenges, and opportunities.
Browse 145 market data tables and 60 figures spread through 195 pages and in-depth TOC on “European Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90)), by Application (Oncology, Thyroid, Cardiology) - Forecasts to 2020”
Early buyers will receive 10% customization on reports.
This report studies the European nuclear medicine/radiopharmaceuticals market for the forecast period of 2015 to 2020. This market is expected to reach $1.62 Billion by 2020 from $1.09 Billion in 2015, at a CAGR of 8.2% during the forecast period (2015 to 2020).
The European nuclear medicine/radiopharmaceuticals market is segmented on the basis of type, application, and country.
Based on type, the European nuclear medicine/radiopharmaceuticals market is categorized into diagnostic and therapeutic radioisotopes. In 2015, the diagnostic segment accounts for a major share of the European nuclear medicine/radiopharmaceuticals market. The diagnostic radiopharmaceuticals market is further segmented into SPECT and PET radioisotopes. In 2015, the SPECT segment accounts for the largest share of the European nuclear medicine/radiopharmaceuticals diagnostic market. The therapeutic radiopharmaceuticals market is further segmented into beta emitters, alpha emitters, and brachytherapy. In 2015, the beta emitters segment accounts for the largest share of the European nuclear medicine/radiopharmaceuticals therapeutic market.
Based on application, the European nuclear medicine/radiopharmaceuticals market is segmented into SPECT, PET, and therapeutic applications. In 2015, the cardiology application accounts for the largest share of European nuclear medicine SPECT market. The PET market is dominated by oncology applications and therapeutic market is dominated by thyroid applications.
On the basis of country, the market is divided into Germany, France, Italy, U.K., Spain, Russia, and the Rest of Europe (RoE). The Rest of Europe comprises Sweden, Switzerland, Poland, Denmark, The Netherlands, and Belgium, among others. In 2015, Germany accounts for the largest share of the European nuclear medicine/radiopharmaceuticals market, followed by France, Italy, and U.K.
Factors such as increasing preference for SPECT and PET scans, advances in radiotracers, advent of alpha radio immunotherapy-based targeted cancer treatment, increasing incidence & mortality rate of cancer and cardiac ailments are driving the growth of this market. However, factors such as shorter half-life of radiopharmaceuticals, competition from conventional diagnostic procedures are hindering the growth of this market.
Some of the major players in the European nuclear medicine market include Cardinal Health Inc. (U.S.), GE Healthcare (U.K.), Bracco Imaging S.p.A (Italy), Eczacibasi-Monrol Nuclear Products (Turkey), Nordion, Inc. (Canada), Advanced Accelerator Applications S.A. (France), Bayer Healthcare (Germany), Lantheus Medical Imaging, Inc. (U.S.), IBA Molecular Imaging (Belgium), and Mallinckrodt plc (Ireland).
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
